Glucosamine

Glucosamine comes with a striking longevity headline: in large cohorts, people who take it habitually die at about 15% lower rates. That signal is observational and disappeared in a larger, more carefully adjusted analysis, and the joint-pain benefit it was sold on is small and rests almost entirely on one manufacturer's prescription product.

Don't take glucosamine for longevity. If you want to try it for knee osteoarthritis, use prescription-grade crystalline glucosamine sulfate, 1,500 mg once a day, and stop after about 3 months if your pain hasn't clearly improved — after exercise and weight loss, not instead of them. If you take warfarin, avoid it or have your clotting checked closely.

The death-rate signal is probably the kind of person who takes it

Glucosamine is an amino sugar and a building block of cartilage. The longevity interest comes from UK Biobank, where 495,077 adults were followed for a median 8.9 years. The 19% who took glucosamine regularly had about 15% lower death rates overall, roughly 18% lower from cardiovascular disease, 27% from respiratory disease, 26% from digestive disease and 6% from cancer.[1] A companion analysis of 466,039 people without heart disease found about 22% lower cardiovascular death and 18% less coronary heart disease; the ~9% lower stroke rate was borderline.[2] A 2026 pooling of four cohorts put the overall figure at about 16% lower all-cause mortality, and its authors cautioned that the kind of people who take glucosamine, along with other unmeasured differences, could explain part or all of it.[3]

Three things make it unlikely the pill is doing the work.

Users are healthier to begin with. They exercise more, smoke less, eat better and have more money and education, and statistical adjustment can't fully remove that. A methods critique showed that the way these cohorts were built — people already taking glucosamine, who chose to join a study — can turn a true effect of zero into an apparent protective ratio of about 0.82, almost exactly what the studies report.[4]

Tighter analyses weaken it. In the US national health survey, one analysis of 16,686 adults found about 27% lower mortality among the 658 who had taken glucosamine/chondroitin for a year or longer, and its authors noted that otherwise-healthy people may simply be the ones who take supplements.[5] A larger analysis of 38,021 adults from the same survey saw the benefit in simple comparisons, but after extensive adjustment glucosamine users died at about the same rate as non-users.[6] And when the critique's authors compared 20,541 people in the UK with osteoarthritis who newly started glucosamine against 20,541 closely matched non-users — a design built to avoid this bias — cancer rates over about eight years were essentially the same.[7] No study of that design has yet looked at deaths.

Genetic studies disagree. Studies that use inherited gene variants as a stand-in for lifelong exposure are split: one linked genetically higher glucosamine to older parental age at death,[8] another to about 8% lower heart-failure risk,[9] but a third found it raised the risk of melanoma, prostate and other skin cancers (while lowering some others) and concluded that habitual use for disease prevention "cannot be supported."[10]

No randomised trial has tested glucosamine for survival. Treat the association as a hypothesis, not a reason to take it.

The brain: unsettled in both directions

Among about 290,000 middle-aged and older UK adults, glucosamine users developed dementia at about the same rate as non-users.[11] A 2026 study found that glucosamine worsened memory in Alzheimer's-model mice, and in one US hospital system's records, people with dementia who took it had about 25% higher mortality — but those records were matched only for age and basic demographics.[12] A follow-up in a separate US dementia cohort, not yet peer reviewed, found no higher mortality (though its death records were limited), and the faster progression to dementia it hinted at showed up with multivitamins and calcium/vitamin D too, which points to who takes supplements rather than to glucosamine.[13] Until a trial settles it, people with diagnosed dementia have no good reason to start it.

Joints: a small benefit, tied to one product

The independent trials are mostly negative. The largest, publicly funded trial gave 1,583 people with painful knee osteoarthritis glucosamine hydrochloride (1,500 mg), chondroitin, both, the anti-inflammatory drug celecoxib, or placebo for 24 weeks; only celecoxib beat placebo on the main pain measure.[14] An independent pooling of 10 trials and 3,803 patients found a pain difference of just 0.4 cm on a 10-cm scale, below what patients notice, and tiny differences in joint space.[15]

The positive trials nearly all used one product: patented crystalline glucosamine sulfate, a prescription-grade European formulation taken as one 1,500 mg dose a day. Two 3-year trials of about 200 people each found slower joint-space narrowing on X-ray — the placebo groups lost about 0.2–0.3 mm, the glucosamine groups little or none — and modestly better symptoms; both had manufacturer-affiliated authors.[16][17] A retrospective follow-up by manufacturer-linked investigators reported about 57% fewer knee replacements.[18] An older Cochrane review of 20 trials found pain benefit only with that product, and none in the better-designed trials or on the standard pain-and-function scale.[19] In hip osteoarthritis, a 2-year trial of 222 people from family practices, half with only mild disease, found glucosamine sulfate no better than placebo.[20]

Two things explain the split. Product is tangled up with sponsorship: the manufacturer's trials dominate the positive side, and a small 2025 crossover study in 10 healthy adults found the crystalline form gets into the blood no better than ordinary glucosamine sulfate (that study was tiny, and one author works under contract for a supplement maker).[21] And the placebo response is enormous: in the large trial above, 60% of people on placebo had at least a 20% drop in knee pain, which swamps small real effects and makes them easy to inflate.

Most guidelines advise against it. The American College of Rheumatology issued a strong recommendation against for knee, hip and hand osteoarthritis: it considered pharmaceutical-grade products, raised serious concerns about publication bias, and found that the trials at lowest risk of bias show no important benefit over placebo.[22] The Osteoarthritis Research Society International also strongly recommends against it,[23][24] and the UK's National Institute for Health and Care Excellence tells doctors not to offer it.[25] The US orthopaedic surgeons' guideline says it "may be helpful" for mild-to-moderate knee osteoarthritis but rates the evidence as limited.[26] Only a European osteoporosis-and-osteoarthritis society clearly recommends it, and only the prescription crystalline sulfate for the knee,[27] and a 2024 review of 25 guidelines found its drug advice agreed least with the NICE, American College of Rheumatology and Australian GP guidelines.[28]

What it might be doing

It supplies the raw material for cartilage, though it is unclear whether oral doses deliver enough to matter. It dampens inflammatory signalling in cartilage cells; in one small crossover trial, glucosamine plus chondroitin lowered the inflammation marker C-reactive protein by about 23%, a statistically marginal result.[29] And in a lab study it mimicked a low-carbohydrate diet, extending average lifespan in worms by about 8% and modestly extending survival in old mice, more clearly in females.[30] None is proven to explain the human death-rate signal, though the anti-inflammatory effect is the leading candidate, and the animal doses and timing don't translate directly to a supplement.

Who should be careful

Pooled trials show side effects no more common than on placebo.[31] The rarer problems show up in drug-safety reports instead.

Warfarin. Drug-safety agencies have collected more than 40 reports of a raised INR (international normalized ratio, a measure of how long blood takes to clot) in people on warfarin or other coumarin-type blood thinners after they started glucosamine, with or without chondroitin. Some had serious bleeding; in most, the INR fell back once glucosamine was stopped. Nobody knows why it happens or how often.[32][33] There are no studies or case reports with the newer direct oral anticoagulants (apixaban, rivaroxaban, dabigatran, edoxaban), which is not proof of safety.

Shellfish allergy. Low risk on a small evidence base. The allergy proteins sit in the flesh, not the shell, and in a double-blind challenge all 15 people with confirmed shrimp allergy tolerated 1,500 mg of shrimp-derived glucosamine — though only for the specific products tested.[34] About 7 in 10 Australian adverse-reaction reports for glucosamine and chondroitin products (2000–2011) were allergic-type reactions, in people whose allergy history is unknown.[35]

Blood sugar. In a randomised trial of 407 overweight middle-aged women, 2.5 years of glucosamine sulfate did not change long-term blood sugar (HbA1c) or new diabetes,[36] and in a records study of 304 people with type 2 diabetes it was not linked to any meaningful change.[37] UK Biobank users had about 17% less new type 2 diabetes, an observational link open to the same healthy-user bias.[38] Studies in people who already had impaired glucose tolerance were more likely to find an effect.[39]

Eye pressure. In one small randomised trial of 88 people, eye pressure rose by 2 mmHg or more in about a third of glucosamine users against one in eight on placebo;[40] a second small trial in people with normal eye pressure found no difference,[41] and Finnish biobank data linked earlier use to more than twice the risk of open-angle glaucoma, an observational finding.[42]

What to actually do

  1. Don't start it for longevity. If you already take it for your joints, the death-rate association is at most a possible bonus.
  2. Knee osteoarthritis only, and only after the basics. Exercise, weight loss and topical anti-inflammatory gels have far stronger evidence. If you still want to try it: prescription-grade crystalline glucosamine sulfate, 1,500 mg once a day (not 500 mg three times). Generic hydrochloride and cheap generic sulfate have a largely negative record; choose a third-party-tested product.
  3. Give it about 3 months, then stop if it hasn't clearly helped. No guideline sets a trial period; this is a sensible personal rule.
  4. Skip combination products. Glucosamine-plus-chondroitin rests on the same contested trials, and the major guidelines advise against the combination too.
  5. On warfarin: avoid it, or have your INR checked closely. On any other blood thinner: tell your prescriber.
  6. With diabetes or prediabetes, check your glucose after starting. With glaucoma or high eye pressure, tell your eye doctor and have the pressure rechecked. With a severe shellfish allergy, choose a corn-fermented ("vegetarian") product. In pregnancy or breastfeeding, avoid it — there are too few data.

Further reading

  • Li ZH et al. Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study. Ann Rheum Dis 2020.[43]
  • Suissa K et al. Glucosamine and lower mortality and cancer incidence: Selection bias in the observational studies. Pharmacoepidemiol Drug Saf 2022.[44]
  • King DE, Xiang J. Glucosamine/Chondroitin and Mortality in a US NHANES Cohort. J Am Board Fam Med 2020.[45]
  • Wu Y et al. Association between genetically proxied glucosamine and risk of cancer and non-neoplastic disease: a Mendelian randomization study. Front Genet 2024.[46]
  • Clegg DO et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006.[47]
  • Wandel S et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 2010.[48]
  • Reginster JY et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001.[49]
  • Bruyère O et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation. Osteoarthritis Cartilage 2008.[50]
  • Kolasinski SL et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol 2020.[51]
  • Bruyère O et al. An updated algorithm recommendation for the management of knee osteoarthritis from the ESCEO. Semin Arthritis Rheum 2019.[52]
  • Weimer S et al. D-glucosamine supplementation extends life span of nematodes and of ageing mice. Nat Commun 2014.[53]
— § —